Ruben Mesa, MD | Authors


Challenges Remain in the Treatment Landscape for Myelofibrosis

April 04, 2020

Ruben Mesa, MD, discusses the current challenges in the treatment landscape for researchers treating myelofibrosis (MF) and how a greater understanding of why patients relapse will help investigators overcome these challenges.

Mesa Advises Community Oncologists on JAK Inhibitors for Intermediate-Risk Myelofibrosis

November 22, 2019

Ruben Mesa, MD, director of the Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, gives advice on using the JAK inhibitors ruxolitinib and fedratinib in the community setting for patients with intermediate-risk myelofibrosis.